Patent AT-E400297-T1: [Translated] CTGF AS A TARGET MOLECULE IN THE TREATMENT OF MICROALBUMINURIA IN PATIENTS WITH DIABETIC NEPHROPATHY
The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| bureauCode |
[
"009:25"
]
|
| contactPoint |
{
"fn": "NIH/NCBI Data Team",
"@type": "vcard:Contact",
"hasEmail": "mailto:info@ncbi.nlm.nih.gov"
}
|
| description | The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Official Data Source",
"mediaType": "text/html",
"description": "Access the complete Patent AT-E400297-T1: [Translated] CTGF AS A TARGET MOLECULE IN THE TREATMENT OF MICROALBUMINURIA IN PATIENTS WITH DIABETIC NEPHROPATHY on the official website.",
"downloadURL": "https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400297-T1"
}
]
|
| identifier | https://healthdata.gov/api/views/tp3e-ysr6 |
| issued | 2025-09-05 |
| keyword |
[
"chemistry",
"innovation",
"patent",
"pubchem",
"research"
]
|
| landingPage | https://healthdata.gov/d/tp3e-ysr6 |
| modified | 2025-09-06 |
| programCode |
[
"009:066"
]
|
| publisher |
{
"name": "National Center for Biotechnology Information (NCBI)",
"@type": "org:Organization"
}
|
| theme |
[
"NIH"
]
|
| title | Patent AT-E400297-T1: [Translated] CTGF AS A TARGET MOLECULE IN THE TREATMENT OF MICROALBUMINURIA IN PATIENTS WITH DIABETIC NEPHROPATHY |
